Lonza to Expand ADC Manufacturing Capacity
News Jan 10, 2013
Lonza has announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland.
Oncology therapeutics including ADCs represent one of the fastest growing segments of the pharma and biotech industry and the deployment of ADC targeted therapies has intensified in recent years.
Because cGMP manufacturing of ADCs presents unique challenges, facilities must be designed to handle both biological species and highly potent cytotoxic small molecule drugs.
Lonza has been a pioneer in the manufacturing of ADCs since its initial investment in 2006 which established manufacturing suites for both small and large scale projects, dedicated Research & Development labs, and Quality Control facilities specifically for ADCs.
Since 2010, Lonza has validated large scale manufacturing of platform technologies primarily utilized by ADC drug developers.
The expansion of the ADC facility will double the existing large-scale manufacturing capacity in Visp while allowing current operations to continue without interruption.
It is the next step in bringing challenging new technologies to one of Lonza’s main sites.
The capacity expansion, expected to be complete in the second quarter of 2014, has the potential to bring new job opportunities across all functions in Visp.
“We have witnessed significant growth in the ADC market in the past 24 months and this investment is necessary to continue to support the growing product demands from our customers” said Stefan Stoffel, Head of Lonza’s Chemical Manufacturing business unit.
Stoffel continued, “Lonza Visp will continue to offer a fully integrated end-to-end development and manufacturing solution for ADCs, including the cytotoxic small molecules used in these products and all associated analytics. In addition, Lonza can support protein development and manufacturing via our global biologics development and manufacturing sites.”
Lonza’s continued investment to increase ADC capacity and highly trained personnel allows its customers to capitalize on the unique infrastructure of the Visp site and limit their own investment in the expertise, assets, and infrastructure required to work with these highly potent biological products in a highly regulated environment.
BIA Separations appoints Pete Gagnon as Chief Scientific OfficerNews
Appointment will drive new product and applications development.READ MORE
PPD and Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug DevelopmentNews
Will shorten timelines, reduce costs and simplify contracting process in pediatric programs.READ MORE